Open AccessCoccidioidomycosis in Patients Treated With Ruxolitinib
Author(s) -
Yael Kusne,
Kathryn E. Kimes,
Fionna Feller,
Roberto L. Patron,
Juan GeaBanacloche,
Janis E. Blair,
Holenarasipur R. Vikram,
Neil M. Ampel
Publication year - 2020
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofaa167
Subject(s) - ruxolitinib , medicine , serology , immunology , antibody , bone marrow , myelofibrosis
We report 8 cases of coccidioidomycosis associated with ruxolitinib treatment. Among 135 patients living in the coccidioidal-endemic region receiving ruxolitinib, 5 cases were diagnosed after starting and 4 had extrathoracic dissemination. Periodic serological screening while on ruxolitinib is warranted for patients residing in the coccidioidal-endemic region.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom